Predictors of orphan drug approval in the European Union.
about
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?The influence of the European paediatric regulation on marketing authorisation of orphan drugs for childrenOrphan drug development is not taking off.Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
P2860
Predictors of orphan drug approval in the European Union.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Predictors of orphan drug approval in the European Union.
@en
Predictors of orphan drug approval in the European Union.
@nl
type
label
Predictors of orphan drug approval in the European Union.
@en
Predictors of orphan drug approval in the European Union.
@nl
prefLabel
Predictors of orphan drug approval in the European Union.
@en
Predictors of orphan drug approval in the European Union.
@nl
P2093
P2860
P1476
Predictors of orphan drug approval in the European Union.
@en
P2093
Hans A Büller
Harald E Heemstra
Hubert G M Leufkens
Remco L de Vrueh
Sonja van Weely
P2860
P2888
P304
P356
10.1007/S00228-007-0454-6
P577
2008-01-22T00:00:00Z